Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>Abstract</jats:title><jats:sec><jats:title>Purpose</jats:title><jats:p>We aimed to describe the demographics, cancer subtypes, comorbidities and outcomes of patients with a history of cancer with COVID-19 from March to June 2020. Secondly, we compared patients <jats:italic>hospitalized</jats:italic> with COVID-19 to patients <jats:italic>diagnosed</jats:italic> with COVID-19 and patients <jats:italic>hospitalized</jats:italic> with influenza.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We conducted a cohort study using eight routinely-collected healthcare databases from Spain and the US, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: i) <jats:italic>diagnosed</jats:italic> with COVID-19, ii) <jats:italic>hospitalized</jats:italic> with COVID-19, and iii) <jats:italic>hospitalized</jats:italic> with influenza in 2017-2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We included 118,155 patients with a cancer history in the COVID-19 <jats:italic>diagnosed</jats:italic> and 41,939 in the COVID-19 <jats:italic>hospitalized</jats:italic> cohorts. The most frequent cancer subtypes were prostate and breast cancer (range: 5-19% and 1-14% in the <jats:italic>diagnosed</jats:italic> cohort, respectively). Hematological malignancies were also frequent, with non-Hodgkin’s lymphoma being among the 5 most common cancer subtypes in the <jats:italic>diagnosed</jats:italic> cohort. Overall, patients were more frequently aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 8% to 14% and from 18% to 26% in the <jats:italic>diagnosed</jats:italic> and h<jats:italic>ospitalized</jats:italic> COVID-19 cohorts, respectively. Patients hospitalized with influenza (n=242,960) had a similar distribution of cancer subtypes, sex, age and comorbidities but lower occurrence of adverse events.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Patients with a history of cancer and COVID-19 have advanced age, multiple comorbidities, and a high occurence of COVID-19-related events. Additionaly, hematological malignancies were frequent in these patients.This observational study provides epidemiologic characteristics that can inform clinical care and future etiological studies.</jats:p></jats:sec>

Original publication

DOI

10.1101/2021.01.12.21249672

Type

Journal article

Publisher

Cold Spring Harbor Laboratory

Publication Date

15/01/2021